1953. Respiratory Syncytial Virus (RSV) Hospitalizations of US Preterm Infants Born at 29-35 Weeks Gestational Age: Proportions by Chronologic Age and Birth Month
Session: Poster Abstract Session: Clinical: Respiratory Track
Saturday, October 7, 2017
Room: Poster Hall CD
Posters
  • Anderson_IDWeek 2017_Final_03Oct17.pdf (446.2 kB)
  • Respiratory Syncytial Virus (RSV) Hospitalizations of US Preterm Infants Born at 29-35 Weeks Gestational Age: Proportions by Chronologic Age and Birth Month

    Background: Respiratory syncytial virus hospitalizations (RSVH) in preterm infants 29–35 weeks gestational age (wGA) are often severe, frequently resulting in intensive care unit admission and the need for invasive mechanical ventilation. Assessing both chronologic age and birth month (a marker of RSV-seasonal exposure) may provide a practical approach to stratifying RSVH risk in otherwise healthy preterm infants 29–35 wGA. The objective of this study was to evaluate the comparative distributions of community-acquired RSVH by chronologic age and birth month among infants 29–35 wGA not receiving immunoprophylaxis.

    Methods: The SENTINEL1 study (NCT02273882) was conducted at 46 US sites over 2 RSV seasons (1 Oct–30 Apr) in 2014–2015 and 2015–2016. At each site, all infants 29–35 wGA with community-acquired, laboratory-confirmed RSV were included if aged <12 mo, hospitalized for ≥24 h with RSV, and had not received RSV immunoprophylaxis. Information on RSVH by chronologic age, gestational age, and birth month was systematically collected on all eligible infants.

    Results: 1378 infants 29–35 wGA were identified over 2 RSV seasons. Case distribution by chronologic age and gestational age is presented in Figure 1, and distribution by birth month and gestational age is presented in Figure 2. Among infants 29–32 wGA, 55% of RSVH occurred among those <4 mo chronologic age. Among infants 33–34 wGA and 35 wGA, 55% of RSVH occurred among those <3 mo chronologic age. Among infants 29–32 wGA, 67% of RSVH occurred among infants born Aug-Jan. Among infants 33–34 wGA and 35 wGA, 66% and 65% of RSVH, respectively, occurred in infants born Sep-Jan.

    Conclusion: RSVH remains an important problem among preterm infants 29–35 wGA. Incorporating chronologic age and birth month can enhance risk stratification around prevention and improve anticipatory guidance to families of preterm infants.

    Study supported by AstraZeneca.

     

     

     

    Evan J. Anderson, MD, Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA, Eric A. Simões, MB, BS, DCH, MD, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, Michael L. Forbes, MD, Department of Pediatrics, Akron Children’s Hospital, Akron, OH, Paul A. Checchia, MD, Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston, TX, Joseph B. Domachowske II, MD, FIDSA, FPIDS, Pediatrics, Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, Leonard R. Krilov, MD, Children’s Medical Center, NYU Winthrop, Mineola, NY, Natasha B. Halasa, MD, MPH, FPIDS, Vanderbilt University Medical Center, Nashville, TN, John P. Devincenzo, MD, Children's Foundation Research Institute, Le Bonheur Children's Hospital, Memphis, TN, Christopher Rizzo, MD, FAAP, AstraZeneca, Gaithersburg, MD, Kimmie K. McLaurin, MS, Department of Health Economics and Outcomes Research, AstraZeneca, Gaithersburg, MD and Christopher S. Ambrose, MD, MBA, Department of US Medical Affairs, AstraZeneca, Gaithersburg, MD

    Disclosures:

    E. J. Anderson, AbbVie: Consultant , Consulting fee
    NovaVax: Research Contractor , Research support
    Regeneron: Research Contractor , Research grant
    MedImmune: Research Contractor , Research grant and Research support

    E. A. Simões, AstraZeneca/MedImmune: Investigator , Research support

    M. L. Forbes, AstraZeneca/MedImmune: Investigator and Speaker's Bureau , Research support and Speaker honorarium

    P. A. Checchia, AstraZeneca/MedImmune: Investigator , Research support

    J. B. Domachowske II, AstraZeneca/MedImmune: Investigator , Research support

    L. R. Krilov, AstraZeneca/MedImmune: Consultant , Research grant and Research support

    N. B. Halasa, Sanofi Pasteur: Research Contractor , Research support
    Astra Zeneca: Research Contractor , Grant recipient

    J. P. Devincenzo, AstraZeneca/MedImmune: Investigator , Research support

    C. Rizzo, AstraZeneca: Employee , Salary

    K. K. McLaurin, AstraZeneca: Employee , Salary

    C. S. Ambrose, AstraZeneca: Employee , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.